Maxim’s Jason Kolbert highlights a vast 196% upside potential for Brainstorm stock, backing fundamentals for this “pivotal” drug maker.
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced that new data from the Company’s Phase 2 study of NurOwn® in ALS were presented by lead …
Maxim Group analyst Jason Kolbert came out with an update on Brainstorm Cell Therapeutics (NASDAQ:BCLI), as the company announced that it received a Notice of Allowance from …
